15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Iovance Biotherapeutics Inc, 6 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $7.00 to $14.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $10.29 sits 18% above the current $8.71. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.29 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy686%
Hold114%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Iovance Biotherapeutics Inc.
As of Sep, 6 of 7 firms rate IOVA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IOVA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.16 – $-0.07 · 7 analysts · -41% YoY
Next period, 7 analysts expect Iovance Biotherapeutics Inc to earn $-0.11 a share (range $-0.16 – $-0.07), versus $-0.18 a year earlier. Full-year consensus is $-0.50, growing to $-0.29 the year after.
REVENUE · NEXT QUARTER
$120.7M
Range $102.8M – $134.9M · 7 analysts · +39% YoY
Revenue is expected to reach $120.7M (range $102.8M – $134.9M), +39.1% year-over-year. Full-year consensus is $401.5M, rising to $557.4M next year.
Top analysts covering Iovance Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IOVA.
#1
Geulah Livshits
Chardan Capital · Rank #85
Buy
$14.00+60.7% to target
Overall win rate
46%
+ Follow
#2
Joseph Catanzaro
Piper Sandler · Rank #272
Hold
$6.00-31.1% to target
Overall win rate
41%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$9.00+3.3% to target
Overall win rate
34%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #366
Buy
$8.00-8.2% to target
Overall win rate
32%
+ Follow
#5
DD
David Dai
UBS
Hold
$7.00-19.6% to target
Coverage
—
+ Follow
IOVA stock forecast FAQ
What is IOVA's average 12-month price target?+
The 7 analysts with a live target average $10.29 for Iovance Biotherapeutics Inc over the next 12 months, ranging from a $14.00 high to a $7.00 low.
Is IOVA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 6 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IOVA?+
The Street-high target is $14.00 (Chardan Capital), and the Street-low is $7.00 (UBS). The average of all 7 active targets is $10.29.
How many Wall Street analysts cover IOVA?+
7 analysts have an active rating on Iovance Biotherapeutics Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering IOVA?+
Among analysts who currently cover IOVA, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #85). Their current call is Buy with a $14.00 target.
What is Iovance Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.16 – $-0.07) across 7 analysts. Full-year EPS is projected at $-0.50, rising to $-0.29 the following year.
How much revenue is Iovance Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $120.7M (range $102.8M – $134.9M). Full-year revenue is projected at $401.5M, growing to $557.4M next year.
Have analysts been upgrading or downgrading IOVA lately?+
As of Sep, 6 of 7 firms rate IOVA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IOVA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
